Immunotherapy News and Research

Latest Immunotherapy News and Research

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

ESMO Congress 2024: Shaping the future of anticancer therapies

The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care.

21 Feb 2024

Pioneering cell-based treatment for melanoma offered at Siteman Cancer Center

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.

20 Feb 2024

Aging alters fibroblasts to promote pancreatic cancer growth

Older people may be at greater risk of developing pancreatic cancer and have poorer prognoses because of age-related changes in cells in the pancreas called fibroblasts, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

20 Feb 2024

Unveiling the role of CD24-Siglec10 axis in tumor immune evasion

Announcing a new article publication for BIO Integration journal. CD24, also known as heat-stable protein, is a highly glycosylated glycosylphosphatidylinositol junction membrane protein.

20 Feb 2024

Understanding the impact of spring allergies on different body systems

If you suffer from spring allergies, you already know you tend to feel miserable once pollen season descends.

19 Feb 2024

Innovative immunotherapy targets rare melanoma subtypes

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

16 Feb 2024

City of Hope cures oldest person of blood cancer and achieves HIV remission

City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a blood cancer and then achieve remission for HIV after receiving a blood stem cell transplant from a donor with a rare genetic mutation.

15 Feb 2024

Innovative treatment increases survival of people with malignant mesothelioma, trial shows

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.

15 Feb 2024

Combination therapy shows promise in targeting latent HIV reservoirs

Antiretroviral therapies (ART) stop HIV replication in its tracks, allowing people with HIV to live relatively normal lives.

15 Feb 2024

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC).

15 Feb 2024

Researchers develop enhanced immunotherapy for multiple myeloma treatment

Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor.

14 Feb 2024

Identifying immunotherapy resistance in liver cancer linked to steatotic disease

A research team of Canadian and French scientists, led by INRS professor Maya Saleh, has been investigating immunotherapy resistance in certain patients with hepatocellular carcinoma (HCC) associated with steatotic liver disease.

14 Feb 2024

Novel three-drug combo shows promise in advanced HER2-negative breast cancer treatment

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.

14 Feb 2024

Phosphoproteomic profiling reveals the complex interplay of immune cells in tumors

Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and others, have unveiled a detailed understanding of immune responses in cancer, marking a significant development in the field.

14 Feb 2024

Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells

The effect of Interleukin-24 (IL-24) on CSCs and CAR-T cell therapy.

14 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024